Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib plus topical corticosteroids in Japanese children with moderate to severe atopic dermatitis
jRCT2061240088Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Placebo / Upadacitinib + Topical Corticosteroids with Upadacitinib + Topical Corticosteroids (2 arms). Primary endpoints: Percentage of participants achieving EASI 75 at Week 12 and Number of participants with adverse events. Started Dec 2024; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2061240088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240088.